Literature DB >> 25121571

Cortical thickness in ALS: towards a marker for upper motor neuron involvement.

Renée Walhout1, Henk-Jan Westeneng1, Esther Verstraete1, Jeroen Hendrikse2, Jan H Veldink1, Martijn P van den Heuvel3, Leonard H van den Berg1.   

Abstract

OBJECTIVE: Examine whether cortical thinning is a disease-specific phenomenon across the spectrum of motor neuron diseases in relation to upper motor neuron (UMN) involvement.
METHODS: 153 patients (112 amyotrophic lateral sclerosis (ALS), 19 patients with a clinical UMN phenotype, 22 with a lower motor neuron (LMN) phenotype), 60 healthy controls and 43 patients with an ALS mimic disorder were included for a cross-sectional cortical thickness analysis. Thirty-nine patients with ALS underwent a follow-up scan. T1-weighted images of the brain were acquired using a 3 T scanner. The relation between cortical thickness and clinical measures, and the longitudinal changes were examined.
RESULTS: Cortical thickness of the precentral gyrus (PCG) was significantly reduced in ALS (p=1.71×10(-13)) but not in mimic disorders (p=0.37) or patients with an LMN phenotype (p=0.37), as compared to the group of healthy controls. Compared to patients with ALS, patients with a UMN phenotype showed an even lower PCG cortical thickness (p=1.97×10(-3)). Bulbar scores and arm functional scores showed a significant association with cortical thickness of corresponding body regions of the motor homunculus. Longitudinal analysis revealed a decrease of cortical thickness in the left temporal lobe of patients with ALS (parahippocampal region p=0.007 and fusiform cortex p=0.001).
CONCLUSIONS: PCG cortical thinning was found to be specific for motor neuron disease with clinical UMN involvement. Normal levels of cortical thickness in mimic disorders or LMN phenotypes suggest that cortical thinning reflects pathological changes related to UMN involvement. Progressive cortical thinning in the temporal lobe suggests recruitment of non-motor areas, over time. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  ALS; MOTOR NEURON DISEASE; MRI

Mesh:

Substances:

Year:  2014        PMID: 25121571     DOI: 10.1136/jnnp-2013-306839

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  45 in total

1.  High-Resolution 7T MR Imaging of the Motor Cortex in Amyotrophic Lateral Sclerosis.

Authors:  M Cosottini; G Donatelli; M Costagli; E Caldarazzo Ienco; D Frosini; I Pesaresi; L Biagi; G Siciliano; M Tosetti
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-17       Impact factor: 3.825

2.  Age at symptom onset influences cortical thinning distribution and survival in amyotrophic lateral sclerosis.

Authors:  Pilar M Ferraro; Corrado Cabona; Giuseppe Meo; Claudia Rolla-Bigliani; Lucio Castellan; Matteo Pardini; Matilde Inglese; Claudia Caponnetto; Luca Roccatagliata
Journal:  Neuroradiology       Date:  2021-03-04       Impact factor: 2.804

Review 3.  Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Suvi Häkkinen; Stephanie A Chu; Suzee E Lee
Journal:  Neurobiol Dis       Date:  2020-09-02       Impact factor: 5.996

Review 4.  Neuroimaging as a New Diagnostic Modality in Amyotrophic Lateral Sclerosis.

Authors:  Esther Verstraete; Bradley R Foerster
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

5.  Linking contemporary high resolution magnetic resonance imaging to the von Economo legacy: A study on the comparison of MRI cortical thickness and histological measurements of cortical structure.

Authors:  Lianne H Scholtens; Marcel A de Reus; Martijn P van den Heuvel
Journal:  Hum Brain Mapp       Date:  2015-05-19       Impact factor: 5.038

6.  Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies.

Authors:  Pilar M Ferraro; Charles Jester; Christopher A Olm; Katerina Placek; Federica Agosta; Lauren Elman; Leo McCluskey; David J Irwin; John A Detre; Massimo Filippi; Murray Grossman; Corey T McMillan
Journal:  Neurobiol Aging       Date:  2018-04-17       Impact factor: 4.673

7.  Structural explanation of poor prognosis of amyotrophic lateral sclerosis in the non-demented state.

Authors:  H-J Kim; S-I Oh; M de Leon; X Wang; K-W Oh; J-S Park; A Deshpande; M Buj; S H Kim
Journal:  Eur J Neurol       Date:  2016-10-18       Impact factor: 6.089

Review 8.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 9.  Pathophysiological and diagnostic implications of cortical dysfunction in ALS.

Authors:  Nimeshan Geevasinga; Parvathi Menon; P Hande Özdinler; Matthew C Kiernan; Steve Vucic
Journal:  Nat Rev Neurol       Date:  2016-09-23       Impact factor: 42.937

10.  Significance of CSF NfL and tau in ALS.

Authors:  Stefanie Schreiber; Nicola Spotorno; Frank Schreiber; Julio Acosta-Cabronero; Jörn Kaufmann; Judith Machts; Grazyna Debska-Vielhaber; Cornelia Garz; Daniel Bittner; Nathalie Hensiek; Reinhard Dengler; Susanne Petri; Peter J Nestor; Stefan Vielhaber
Journal:  J Neurol       Date:  2018-09-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.